These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 31026547

  • 21. Synergistic antitumor activity of a self-assembling camptothecin and capecitabine hybrid prodrug for improved efficacy.
    Ma W, Su H, Cheetham AG, Zhang W, Wang Y, Kan Q, Cui H.
    J Control Release; 2017 Oct 10; 263():102-111. PubMed ID: 28082170
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic Nanoreactors as In Vivo Nanoplatforms for Cancer Therapy.
    Mukerabigwi JF, Ge Z, Kataoka K.
    Chemistry; 2018 Oct 22; 24(59):15706-15724. PubMed ID: 29572992
    [Abstract] [Full Text] [Related]

  • 23. Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.
    Fu Q, Wang Y, Ma Y, Zhang D, Fallon JK, Yang X, Liu D, He Z, Liu F.
    Sci Rep; 2015 Jul 13; 5():12023. PubMed ID: 26166066
    [Abstract] [Full Text] [Related]

  • 24. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
    Hou M, Gao YE, Shi X, Bai S, Ma X, Li B, Xiao B, Xue P, Kang Y, Xu Z.
    Acta Biomater; 2018 Sep 01; 77():228-239. PubMed ID: 30006314
    [Abstract] [Full Text] [Related]

  • 25. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
    He X, Cai K, Zhang Y, Lu Y, Guo Q, Zhang Y, Liu L, Ruan C, Chen Q, Chen X, Li C, Sun T, Cheng J, Jiang C.
    ACS Appl Mater Interfaces; 2018 Nov 21; 10(46):39455-39467. PubMed ID: 30362704
    [Abstract] [Full Text] [Related]

  • 26. "Bottom-up" Construction of Multi-Polyprodrug-Arm Hyperbranched Amphiphiles for Cancer Therapy.
    Sun P, Chen D, Deng H, Wang N, Huang P, Jin X, Zhu X.
    Bioconjug Chem; 2017 May 17; 28(5):1470-1480. PubMed ID: 28441015
    [Abstract] [Full Text] [Related]

  • 27. Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy.
    Sun B, Luo C, Yu H, Zhang X, Chen Q, Yang W, Wang M, Kan Q, Zhang H, Wang Y, He Z, Sun J.
    Nano Lett; 2018 Jun 13; 18(6):3643-3650. PubMed ID: 29726685
    [Abstract] [Full Text] [Related]

  • 28. Reduction stimuli-responsive unimolecular polymeric prodrug based on amphiphilic dextran-framework for antitumor drug delivery.
    Bai S, Gao YE, Ma X, Shi X, Hou M, Xue P, Kang Y, Xu Z.
    Carbohydr Polym; 2018 Feb 15; 182():235-244. PubMed ID: 29279120
    [Abstract] [Full Text] [Related]

  • 29. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
    Xu Z, Hou M, Shi X, Gao YE, Xue P, Liu S, Kang Y.
    Biomater Sci; 2017 Feb 28; 5(3):444-454. PubMed ID: 28058423
    [Abstract] [Full Text] [Related]

  • 30. Starburst Diblock Polyprodrugs: Reduction-Responsive Unimolecular Micelles with High Drug Loading and Robust Micellar Stability for Programmed Delivery of Anticancer Drugs.
    Shi X, Hou M, Ma X, Bai S, Zhang T, Xue P, Zhang X, Liu G, Kang Y, Xu Z.
    Biomacromolecules; 2019 Mar 11; 20(3):1190-1202. PubMed ID: 30658038
    [Abstract] [Full Text] [Related]

  • 31. Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.
    Zhang F, Zhu G, Jacobson O, Liu Y, Chen K, Yu G, Ni Q, Fan J, Yang Z, Xu F, Fu X, Wang Z, Ma Y, Niu G, Zhao X, Chen X.
    ACS Nano; 2017 Sep 26; 11(9):8838-8848. PubMed ID: 28858467
    [Abstract] [Full Text] [Related]

  • 32. A pH-responsive prodrug delivery system of 10-HCPT for controlled release and tumor targeting.
    Liu Y, Li D, Guo X, Xu H, Li Z, Zhang Y, Song C, Fan R, Tang X, Zhang Z.
    Int J Nanomedicine; 2017 Sep 26; 12():2227-2242. PubMed ID: 28356739
    [Abstract] [Full Text] [Related]

  • 33. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs.
    Liu X, Lynn BC, Zhang J, Song L, Bom D, Du W, Curran DP, Burke TG.
    J Am Chem Soc; 2002 Jul 03; 124(26):7650-1. PubMed ID: 12083906
    [Abstract] [Full Text] [Related]

  • 34. GSH/pH dual-responsive biodegradable camptothecin polymeric prodrugs combined with doxorubicin for synergistic anticancer efficiency.
    Li J, Hu ZE, Yang XL, Wu WX, Xing X, Gu B, Liu YH, Wang N, Yu XQ.
    Biomater Sci; 2019 Aug 01; 7(8):3277-3286. PubMed ID: 31180396
    [Abstract] [Full Text] [Related]

  • 35. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
    Bala V, Rao S, Boyd BJ, Prestidge CA.
    J Control Release; 2013 Nov 28; 172(1):48-61. PubMed ID: 23928356
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic Vesicular Nanoreactors with Tumor-Specific Activation and Self-Destruction for Synergistic Tumor Ablation.
    Li J, Dirisala A, Ge Z, Wang Y, Yin W, Ke W, Toh K, Xie J, Matsumoto Y, Anraku Y, Osada K, Kataoka K.
    Angew Chem Int Ed Engl; 2017 Nov 06; 56(45):14025-14030. PubMed ID: 28940903
    [Abstract] [Full Text] [Related]

  • 37. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M, Zhu Q, Wu Q, Yin T, Wang L, Yin L, Zhou J.
    J Pharm Sci; 2015 Jun 06; 104(6):2018-2028. PubMed ID: 25820241
    [Abstract] [Full Text] [Related]

  • 38. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
    Shan L, Zhuo X, Zhang F, Dai Y, Zhu G, Yung BC, Fan W, Zhai K, Jacobson O, Kiesewetter DO, Ma Y, Gao G, Chen X.
    Theranostics; 2018 Jun 06; 8(7):2018-2030. PubMed ID: 29556370
    [Abstract] [Full Text] [Related]

  • 39. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G, Wang Z, Li C, Duan G, Wang K, Li Q, Tao T.
    Biomed Pharmacother; 2018 Oct 06; 106():275-284. PubMed ID: 29966971
    [Abstract] [Full Text] [Related]

  • 40. Pd@Pt-GOx/HA as a Novel Enzymatic Cascade Nanoreactor for High-Efficiency Starving-Enhanced Chemodynamic Cancer Therapy.
    Ming J, Zhu T, Yang W, Shi Y, Huang D, Li J, Xiang S, Wang J, Chen X, Zheng N.
    ACS Appl Mater Interfaces; 2020 Nov 18; 12(46):51249-51262. PubMed ID: 33161703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.